Jorge Lopez-Castroman1,2,3, Isabelle Jaussent2, Philip Gorwood4,5,6, Philippe Courtet2,3,7. 1. Department of Psychiatry, CHRU Nimes, Nimes, France. 2. Inserm, U1061, Université Montpellier, Montpellier, France. 3. Fondamental Foundation, Créteil, France. 4. Department of Psychiatry, Sainte-Anne Hospital (CMME), Paris, France. 5. INSERM U894, (Center of Psychiatry and Neurosciences), Paris, France. 6. Department of Psychiatry, University Paris Descartes, Paris, France. 7. Department of Emergency Psychiatry and Post-Acute Care, CHRU Montpellier, Montpellier, France.
Abstract
BACKGROUND: Suicidal thoughts and behaviors could be associated to a poor response to antidepressant treatment, but the exclusion of suicidal patients from randomized clinical trials restricts the available knowledge. In this study, we aimed at defining more precisely the response to antidepressants among suicidal patients and the threshold of suicidality that best predicts a poor response. METHOD: We investigated the short-term response to a new antidepressant treatment of 4,041 depressed outpatients depending on their suicidal status (passive or active suicidal ideation (SI), history of suicide attempts [SAs]), either self-rated or clinician-rated. Depression outcomes, measured with the Hospital Anxiety and Depression Scale, and remission rates were compared depending on suicidal status at baseline using logistic regression models. RESULTS: Using either a qualitative or a quantitative approach to measure SI, we found that suicidal patients were less likely to improve or attain remission, but not more likely to worsen, than nonsuicidal patients. In the multivariate analyses, SI (odds ratio [OR] = 1.40; 95% confidence interval [CI]: 1.18-1.65) and a history of SA (OR = 1.39; 95% CI: 1.16-1.66) were the best predictors of nonremission, independently of the class of antidepressant treatment. CONCLUSION: Antidepressant treatment seems to be less effective among those patients that need it most. Clinical trials including suicidal patients are needed to investigate specific treatment options.
BACKGROUND: Suicidal thoughts and behaviors could be associated to a poor response to antidepressant treatment, but the exclusion of suicidal patients from randomized clinical trials restricts the available knowledge. In this study, we aimed at defining more precisely the response to antidepressants among suicidal patients and the threshold of suicidality that best predicts a poor response. METHOD: We investigated the short-term response to a new antidepressant treatment of 4,041 depressed outpatients depending on their suicidal status (passive or active suicidal ideation (SI), history of suicide attempts [SAs]), either self-rated or clinician-rated. Depression outcomes, measured with the Hospital Anxiety and Depression Scale, and remission rates were compared depending on suicidal status at baseline using logistic regression models. RESULTS: Using either a qualitative or a quantitative approach to measure SI, we found that suicidal patients were less likely to improve or attain remission, but not more likely to worsen, than nonsuicidal patients. In the multivariate analyses, SI (odds ratio [OR] = 1.40; 95% confidence interval [CI]: 1.18-1.65) and a history of SA (OR = 1.39; 95% CI: 1.16-1.66) were the best predictors of nonremission, independently of the class of antidepressant treatment. CONCLUSION: Antidepressant treatment seems to be less effective among those patients that need it most. Clinical trials including suicidal patients are needed to investigate specific treatment options.
Authors: Yasmina M Saade; Ginger Nicol; Eric J Lenze; J Philip Miller; Michael Yingling; Julie Loebach Wetherell; Charles F Reynolds; Benoit H Mulsant Journal: Depress Anxiety Date: 2019-11-04 Impact factor: 6.505
Authors: Eva M Peñas-Lledó; Sebastien Guillaume; Fernando de Andrés; Ana Cortés-Martínez; Jonathan Dubois; Jean Pierre Kahn; Marion Leboyer; Emilie Olié; Adrián LLerena; Philippe Courtet Journal: Transl Psychiatry Date: 2022-10-18 Impact factor: 7.989
Authors: Joana Vanessa Reis; Rita Vieira; Carlos Portugal-Nunes; Ana Coelho; Ricardo Magalhães; Pedro Moreira; Sónia Ferreira; Maria Picó-Pérez; Nuno Sousa; Nuno Dias; João M Bessa Journal: Front Psychiatry Date: 2022-03-21 Impact factor: 4.157
Authors: Dawn F Ionescu; Dong-Jing Fu; Xin Qiu; Rosanne Lane; Pilar Lim; Siegfried Kasper; David Hough; Wayne C Drevets; Husseini Manji; Carla M Canuso Journal: Int J Neuropsychopharmacol Date: 2021-01-20 Impact factor: 5.176